Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

Lunsumio can cause serious and life-threatening neurological problems. Your healthcare provider will check you for neurologic problems during treatment with Lunsumio.

Lunsumio is a first-in-class CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. This dual-targeting activates and ...

Lunsumio remains in the body for several months after the last dose. Regular follow-up is essential to manage any lingering side effects and ensure a smooth transition off the treatment.

New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma – Long-term data confirm fixed ...

Lunsumio and Polivy are a CD20×CD3 T-cell-engaging bispecific antibody and an anti-CD79b antibody-drug conjugate (ADC), respectively. Roche global product development head and chief medical ...

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma – Pivotal Phase III SUNMO study demonstrated an 11.5 ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care These data demonstrate Roche's commitment to providing options ...